Oncology treatment and complications of treatment strategies review
Keywords:
Oncology, Complication, Treatment
Abstract
The tumor surgical treatment and oncology radiation therapy served as medical oncology that contributes to prime importance in comprehensive treatment of malignant tumors. In recent years, various complications roused among the after treatment oncology patients and new treatment measures as increasing cause for concern for patients may vary. The use of individualized integrated treatment method is able to improve the treatment complications. The enhancement on the patient’s overall quality of life has important significance in clinical practice.References
1. Bai H. Manual of tumor diagnosis and treatment for primary physicians. Beijing: Peking University Medical Press; 2008. p. 356.
2. Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, et al. Treatment strategies in follicular lymphomas: Current status and future perspectives. J Clin Oncol 2005; 23(26): 6394–6399. doi: 10.1200/JCO.2005.07.019.
3. Moore A. Breast cancer therapy-looking back to the future. N Engl J Med 2007; 357: 547–549. doi: 10.1056/NEJMe078153.
4. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005; 23(36): 9441–9442. doi: 10.1200/JCO.2005.04.4792.
5. Waechter F, Passweg J, Tamm M, Brutsche M, Herrmann R, et al. Significant progress in palliative treatment of non-small cell lung cancer in the past decade. Chest 2005; 127(3): 738–747. doi: 10.1378/chest.127.3.738.
6. Saltz LB. Managing chemotherapy-induced diarrhea. Clin Adv Hematol Oncol 2006; 4(3): 203–204．
7. Mu Guimei. Effect of nursing intervention on quality of life in oncology patients [J]. Nursing practice and research, 2012, 09 (2): 34–35.
8. Rojas C, Stathis M, Thomas AG, Massuda E, Alt J, et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 2008; 107(2): 469–478. doi: 10.1213/ane.0b013e318172fa74.
9. Ruhlmann C, Herrstedt J. Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther 2010; 10(2): 137–148. doi: 10.1586/era.09.175.
10. Mao Jianjun, Xu Yonghua. Comprehensive nursing of chemotherapy for 180 cases of malignant tumour [J]. Qilu Nursing complex, 2009, 15(13): 71–72 .
2. Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, et al. Treatment strategies in follicular lymphomas: Current status and future perspectives. J Clin Oncol 2005; 23(26): 6394–6399. doi: 10.1200/JCO.2005.07.019.
3. Moore A. Breast cancer therapy-looking back to the future. N Engl J Med 2007; 357: 547–549. doi: 10.1056/NEJMe078153.
4. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005; 23(36): 9441–9442. doi: 10.1200/JCO.2005.04.4792.
5. Waechter F, Passweg J, Tamm M, Brutsche M, Herrmann R, et al. Significant progress in palliative treatment of non-small cell lung cancer in the past decade. Chest 2005; 127(3): 738–747. doi: 10.1378/chest.127.3.738.
6. Saltz LB. Managing chemotherapy-induced diarrhea. Clin Adv Hematol Oncol 2006; 4(3): 203–204．
7. Mu Guimei. Effect of nursing intervention on quality of life in oncology patients [J]. Nursing practice and research, 2012, 09 (2): 34–35.
8. Rojas C, Stathis M, Thomas AG, Massuda E, Alt J, et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 2008; 107(2): 469–478. doi: 10.1213/ane.0b013e318172fa74.
9. Ruhlmann C, Herrstedt J. Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther 2010; 10(2): 137–148. doi: 10.1586/era.09.175.
10. Mao Jianjun, Xu Yonghua. Comprehensive nursing of chemotherapy for 180 cases of malignant tumour [J]. Qilu Nursing complex, 2009, 15(13): 71–72 .
Published
2017-01-19
Issue
Section
Original Research Article
Copyright (c) 2016 Qu Xuening
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.
